Keenova Doses First Patient in Phase 3 Trial for Hammer Toe Treatment
Event summary
- Keenova Therapeutics dosed the first patient in its Phase 3 trial of XIAFLEX for hammer toe treatment on August 20, 2026.
- The double-blind, randomized, placebo-controlled study (KN3835-313) aims to enroll 550 participants across 35 U.S. sites.
- XIAFLEX is currently FDA-approved for urological and orthopedic conditions but is investigational for hammer toe.
- No FDA-approved nonsurgical therapies exist for hammer toe, leaving a significant unmet need in the market.
The big picture
Keenova's Phase 3 trial for XIAFLEX in hammer toe treatment addresses a critical gap in the orthopedic market, where nonsurgical options are lacking. The study's success could position XIAFLEX as a leading therapy for a condition affecting millions of adults in the U.S., particularly older women. The trial's outcomes will be closely watched by investors and competitors in the orthopedic space.
What we're watching
- Regulatory Pathway
- Whether XIAFLEX can secure FDA approval for hammer toe, expanding its orthopedic indications.
- Market Potential
- The size of the addressable market for hammer toe treatments, given the condition's prevalence.
- Clinical Success
- The efficacy and safety data emerging from the Phase 3 trial, which will determine XIAFLEX's viability.